title: [Intravenous immunoglobulin in children with Guillain-Barré syndrome].
abstract: We report our experience with intravenous immunoglobulin (IVIG), plasmapheresis and supportive care in 13 patients with the Guillain-Barré syndrome. Seven of 13 patients received IVIG, 2 plasmapheresis and 4 supportive care. At 15th day after IVIG administration, all patients in this group had improved at least one disability grade. In the plasmapheresis group, 1 improved at 5th day after the procedure. Two of the 4 patients that received supportive care improved at 20th day of evaluation. In the IVIG group, the final scores were lower and had no relapses. These results suggest faster clinical improvement with IVIG when compared with supportive measures.
authors: Departamento de Pediatria, Centro de Neurologia Pediátrica, Hospital de Clínicas, Universidade Federal do Paraná.
authors: I
authors: I
authors: Bruck
authors: S A
authors: SA
authors: Antoniuk
authors: R
authors: R
authors: Cat
authors: A
authors: A
authors: Spessatto
authors: S M
authors: SM
authors: Halick
authors: L R
authors: LR
authors: Bruyn
authors: M
authors: M
authors: Rodrigues
authors: R H
authors: RH
authors: Scola
authors: L C
authors: LC
authors: Werneck
mesh_terms: D002648:Child; D002675:Child, Preschool; D004576:Electromyography; D019054:Evoked Potentials, Motor; D005260:Female; D005500:Follow-Up Studies; D020275:Guillain-Barre Syndrome / Q000628:therapy*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007902:Length of Stay; D008297:Male; D009431:Neural Conduction; D010956:Plasmapheresis; D012720:Severity of Illness Index
chemical_list: D016756:Immunoglobulins, Intravenous